TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Randomized, Double-Blind, 12-Week, Parallel Group, Placebo-Controlled Proof of Concept Study to Investigate the Efficacy and Safety of RG7314 in Individuals With Autism Spectrum Disorders (ASD)
Brief Summary: This multi-center, randomized, double-blind, parallel group, placebo-controlled, proof of concept study will investigate the efficacy and safety of RG7314 in adult participants with ASD. In Stage I of the study, participants will be randomized in 2:1 to receive daily oral doses of 1.5 milligrams (mg) RG7314 or placebo for 12 weeks. After an independent safety review, the study may proceed to Stage II. In Stage II of the study, additional participants will be randomized in 2:1 to receive daily oral doses of 4 mg RG7314 or placebo for 12 weeks. After an independent safety review, Stage III will be started wherein additional participants will be randomized in 2:1 to receive daily oral doses of 10 mg RG7314 or placebo for 12 weeks. During Stage III, safety will be reviewed by independent safety review twice and if no safety signal is observed, then additional participants will be randomized in 1:1:1 either to receive 1.5 milligrams per day (mg/day) or 10 mg/day RG7314 orally or placebo for 12 weeks in Stage IV.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Vasopressin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vasopressin | Intervention Type: DRUG; Name: Vasopressin; Assigned to Arm(s): Vasopressin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Buspirone | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Buspirone | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Buspirone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Buspirone; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: RG7314; Type: EXPERIMENTAL; Interventions: Drug: RG7314 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: RG7314; Assigned to Arm(s): RG7314
D: Arm Label: Aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripiprazole | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Standardized Fecal Microbiota Transplantation for Moderate to Severe Crohn's Diseases
Brief Summary: The gut microbiota is considered to constitute a "microbial organ" which has pivotal roles in the intestinal diseases and body's metabolism. Evidence from animal and human studies strongly supports the link between intestinal bacteria and inflammatory bowel diseases (IBD). Dozens of studies reported its efficacy in treatment of severe Clostridium difficile colitis. Preliminary studies using fecal microbiota transplantation (FMT) for Ulcerative Colitis (UC), Crohn's diseases (CD), irritable bowel syndrome (IBS) and constipation have also met with some success. However, the results on CD is very limited. This marks the initial step in exploring the potential efficacy of fecal bacteriotherapy for CD. The investigators aim to evaluate the effectiveness, durability, and safety of FMT in a cohort of at least 500 patients with CD over a ten-year period


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: Fecal Microbiota Transplantation (FMT), OpenBiome, Other: pretreatment antibiotics | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: Fecal Microbiota Transplantation (FMT), OpenBiome | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Biological: Fecal Microbiota Transplantation (FMT), OpenBiome, Other: pretreatment antibiotics | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Biological: Fecal Microbiota Transplantation (FMT), OpenBiome | Intervention Type: BIOLOGICAL; Name: Fecal Microbiota Transplantation (FMT), OpenBiome; Assigned to Arm(s): 1, 2, 3, 4 | Intervention Type: OTHER; Name: pretreatment antibiotics; Assigned to Arm(s): 1, 3
B: Arm Label: placebo enema; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo enema | Arm Label: Fecal transplant from an unrelated donor; Type: ACTIVE_COMPARATOR; Interventions: Other: Fecal transplant | Intervention Type: OTHER; Name: Fecal transplant; Assigned to Arm(s): Fecal transplant from an unrelated donor | Intervention Type: OTHER; Name: Placebo enema; Assigned to Arm(s): placebo enema
C: Arm Label: Fecal microbiota transplantation; Type: EXPERIMENTAL; Interventions: Procedure: FMT | Arm Label: Traditional treatments; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: FMT; Assigned to Arm(s): Fecal microbiota transplantation
D: Arm Label: Fecal Microbiota Enema; Type: EXPERIMENTAL; Interventions: Biological: Fecal Microbiota Enema | Arm Label: Normal Saline Enema; Type: PLACEBO_COMPARATOR; Interventions: Biological: Normal Saline Enema | Intervention Type: BIOLOGICAL; Name: Fecal Microbiota Enema; Assigned to Arm(s): Fecal Microbiota Enema | Intervention Type: BIOLOGICAL; Name: Normal Saline Enema; Assigned to Arm(s): Normal Saline Enema

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
Brief Summary: The main purpose of the study is to evaluate the efficacy and safety of the study drug known as prasugrel for the reduction of Vaso-Occlusive Crisis events in pediatric participants with sickle cell disease. The study will also investigate reduction in daily pain in children who have sickle cell disease.


Options:
A: Arm Label: Prasugrel; Type: EXPERIMENTAL; Interventions: Drug: Prasugrel | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Prasugrel; Assigned to Arm(s): Prasugrel | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: PROCEDURE; Name: blood transfusion; Assigned to Arm(s): N/A
C: Arm Label: Transfusion Group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: transfusion therapy | Arm Label: Observation Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: transfusion therapy; Assigned to Arm(s): Transfusion Group
D: Arm Label: Blood Transfusion Trial Cohort; Type: ACTIVE_COMPARATOR; Interventions: Biological: Single blood transfusion | Arm Label: Standard Care Trial Cohort; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard care | Arm Label: Standard Care Observational Cohort; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard care | Intervention Type: BIOLOGICAL; Name: Single blood transfusion; Assigned to Arm(s): Blood Transfusion Trial Cohort | Intervention Type: BEHAVIORAL; Name: Standard care; Assigned to Arm(s): Standard Care Observational Cohort, Standard Care Trial Cohort

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue
Brief Summary: To examine if 3 months of treatment with a GLP-1 (glucagon-like-peptide-1) analogue can induce weight loss in obese, non-diabetic patients with a diagnosis within the schizophrenic spectrum.

The investigators will also examine possible associations between GLP-1 treatment and peripheral metabolic parameters such as change in body fat and HbA1c. Moreover, the GLP-1 analogue treatment will be associated with the effects/changes on cognition and subjective quality of life. Possible cerebral effects (pro-cognitive) of the GLP-1 analogue treatment will associated and correlated with changes in the brain, functional magnetic resonance imaging (fMRI).


Options:
A: Arm Label: Olanzapine; Type: EXPERIMENTAL; Interventions: Drug: olanzapine, Behavioral: Wellness education | Arm Label: Olanzapine + Amantadine; Type: EXPERIMENTAL; Interventions: Drug: olanzapine, Drug: amantadine, Drug: metformin, Drug: zonisamide, Behavioral: Wellness education | Arm Label: Olanzapine + Metformin; Type: EXPERIMENTAL; Interventions: Drug: olanzapine, Drug: amantadine, Drug: metformin, Drug: zonisamide, Behavioral: Wellness education | Intervention Type: DRUG; Name: olanzapine; Assigned to Arm(s): Olanzapine, Olanzapine + Amantadine, Olanzapine + Metformin | Intervention Type: DRUG; Name: amantadine; Assigned to Arm(s): Olanzapine + Amantadine, Olanzapine + Metformin | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): Olanzapine + Amantadine, Olanzapine + Metformin | Intervention Type: DRUG; Name: zonisamide; Assigned to Arm(s): Olanzapine + Amantadine, Olanzapine + Metformin | Intervention Type: BEHAVIORAL; Name: Wellness education; Assigned to Arm(s): Olanzapine, Olanzapine + Amantadine, Olanzapine + Metformin
B: Arm Label: metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): metformin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: exenatide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Exenatide | Intervention Type: DRUG; Name: Exenatide; Assigned to Arm(s): exenatide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Bupropion SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion SR | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Oral Tablet | Intervention Type: DRUG; Name: Bupropion SR; Assigned to Arm(s): Bupropion SR | Intervention Type: DRUG; Name: Placebo Oral Tablet; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Usefulness of Point-of-care-testing for C-reactive Protein in Lower Respiratory Tract Infection or Acute Cough
Brief Summary: The aim of this study is to evaluate the usefulness in Russian general practice of C-reactive protein testing in patients with acute cough or lower respiratory tract infections.

In addition to studying the effect of C-reactive protein testing on the prescription of antibiotics, the purpose is to find out whether the frequency of referral to radiography could be reduced.


Options:
A: N/A
B: Intervention Type: BEHAVIORAL; Name: No antibiotics if se-procalcitonin is below stated limit; Assigned to Arm(s): N/A
C: Intervention Type: OTHER; Name: laboratory value procalcitonin; Assigned to Arm(s): N/A
D: Arm Label: C-reactive protein test; Type: EXPERIMENTAL; Interventions: Device: C-reactive protein test | Intervention Type: DEVICE; Name: C-reactive protein test; Assigned to Arm(s): C-reactive protein test

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Usefulness of Point-of-care-testing for C-reactive Protein in Lower Respiratory Tract Infection or Acute Cough
Brief Summary: The aim of this study is to evaluate the usefulness in Russian general practice of C-reactive protein testing in patients with acute cough or lower respiratory tract infections.

In addition to studying the effect of C-reactive protein testing on the prescription of antibiotics, the purpose is to find out whether the frequency of referral to radiography could be reduced.


Options:
A: Arm Label: C-reactive protein test; Type: EXPERIMENTAL; Interventions: Device: C-reactive protein test | Intervention Type: DEVICE; Name: C-reactive protein test; Assigned to Arm(s): C-reactive protein test
B: Arm Label: CRP intervention; Type: EXPERIMENTAL; Interventions: Procedure: Patients will be tested by rapid POC CRP test | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Patients will be tested by rapid POC CRP test; Assigned to Arm(s): CRP intervention
C: Arm Label: iCPR2 intervention; Type: EXPERIMENTAL; Interventions: Other: iCPR2 | Arm Label: iCPR2 control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: iCPR2; Assigned to Arm(s): iCPR2 intervention
D: Arm Label: Antibiotic use feedback letter 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Antibiotic use feedback letter | Arm Label: Antibiotic use feedback letter 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Antibiotic use feedback letter | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Antibiotic use feedback letter; Assigned to Arm(s): Antibiotic use feedback letter 1, Antibiotic use feedback letter 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Gestational Diabetes Mellitus
Brief Summary: It is well-known that women with previous gestational diabetes mellitus are in risk of developing type 2 diabetes later in life; approximately half of the women develop overt type 2 diabetes within the first 10 years after pregnancy. Knowing this, we want to examine the effect of the type 2 diabetes medicine, liraglutide (Victoza), in women with previous gestational diabetes with the aim of reducing the risk of developing type 2 diabetes.


Options:
A: Arm Label: Exenatide; Type: EXPERIMENTAL; Interventions: Drug: Exenatide | Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Intervention Type: DRUG; Name: Exenatide; Assigned to Arm(s): Exenatide | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin
B: Arm Label: Exenatide first, then Placebo; Type: EXPERIMENTAL; Interventions: Drug: Exenatide, Drug: Placebo | Arm Label: Placebo first, then Exenatide; Type: EXPERIMENTAL; Interventions: Drug: Exenatide, Drug: Placebo | Intervention Type: DRUG; Name: Exenatide; Assigned to Arm(s): Exenatide first, then Placebo, Placebo first, then Exenatide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Exenatide first, then Placebo, Placebo first, then Exenatide
C: Arm Label: Liraglutide; Type: EXPERIMENTAL; Interventions: Drug: Liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Liraglutide; Assigned to Arm(s): Liraglutide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Sitagliptin; Type: EXPERIMENTAL; Interventions: Drug: Sitagliptin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sitagliptin; Assigned to Arm(s): Sitagliptin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of DHA (DOCOSAHEXAENOIC ACID) on Attention Deficit and Hyperactivity Disorder
Brief Summary: The purpose of this study is to determine whether docosahexaenoic acid (DHA) is effective in reducing Attention Deficit/Hyperactivity Disorder (ADHD) core symptoms in a clinical sample of children and adolescents with ADHD.


Options:
A: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Omega 3/6 fatty acids | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega 3/6 fatty acids; Assigned to Arm(s): Active | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: ADHD active; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Eicosapentaenoic acid / Docosahexaenoic acid | Arm Label: ADHD Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo dietary intervention (MUFA) in ADHD group | Arm Label: Active Healthy control; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Eicosapentaenoic acid / Docosahexaenoic acid | Arm Label: Healthy placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo dietary intervention (MUFA) in healthy control group | Intervention Type: DIETARY_SUPPLEMENT; Name: Eicosapentaenoic acid / Docosahexaenoic acid; Assigned to Arm(s): ADHD active | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo dietary intervention (MUFA) in ADHD group; Assigned to Arm(s): ADHD Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Eicosapentaenoic acid / Docosahexaenoic acid; Assigned to Arm(s): Active Healthy control | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo dietary intervention (MUFA) in healthy control group; Assigned to Arm(s): Healthy placebo
C: Arm Label: Wheat germ oil; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Wheat germ oil | Arm Label: docosahexaenoic acid; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: docosahexaenoic acid | Intervention Type: DIETARY_SUPPLEMENT; Name: docosahexaenoic acid; Assigned to Arm(s): docosahexaenoic acid | Intervention Type: DIETARY_SUPPLEMENT; Name: Wheat germ oil; Assigned to Arm(s): Wheat germ oil
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Phosphatidylserine-Omega3 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Colored cellulose tainted with fishy odor | Intervention Type: DIETARY_SUPPLEMENT; Name: Phosphatidylserine-Omega3; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Colored cellulose tainted with fishy odor; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of Home Monitoring Versus Hospitalization in Mild Non-Alcoholic Acute Interstitial Pancreatitis
Brief Summary: Acute pancreatitis (AP) is considered a disease requiring in-hospital treatment. We studied the feasibility of home management in AP.The aim of study was to compare 30 day readmission rates in patients with mild non-alcoholic acute pancreatitis (NAAP) randomized to home monitoring versus hospitalization.


Options:
A: Arm Label: Home and hospital treatment groups; Type: N/A; Interventions: N/A
B: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Other: Very early supported discharge (VESD) | Arm Label: Control; Type: OTHER; Interventions: Other: Ordinary rehabilitation | Intervention Type: OTHER; Name: Very early supported discharge (VESD); Assigned to Arm(s): Active | Intervention Type: OTHER; Name: Ordinary rehabilitation; Assigned to Arm(s): Control
C: Arm Label: Psychoeducative intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Psychoeducative intervention | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Psychoeducative intervention; Assigned to Arm(s): Psychoeducative intervention
D: Arm Label: Hospital Inpatient Rehabilitation (HI); Type: ACTIVE_COMPARATOR; Interventions: Other: Hospital Inpatient Rehabilitation | Arm Label: Hybrid Home Programme (HO); Type: ACTIVE_COMPARATOR; Interventions: Other: Hybrid Home Programme (HO) | Intervention Type: OTHER; Name: Hospital Inpatient Rehabilitation; Assigned to Arm(s): Hospital Inpatient Rehabilitation (HI) | Intervention Type: OTHER; Name: Hybrid Home Programme (HO); Assigned to Arm(s): Hybrid Home Programme (HO)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Randomized, Double-Masked, Multicenter, Two Arm Study Comparing the Efficacy and Safety of ESBA1008 Versus EYLEA® in Subjects With Exudative Age-Related Macular Degeneration
Brief Summary: The purpose of this study is to compare the efficacy and safety of ESBA1008 versus EYLEA® in the treatment of exudative age-related macular degeneration.


Options:
A: Arm Label: A: Faricimab 6 mg Q8W; Type: EXPERIMENTAL; Interventions: Drug: Faricimab, Procedure: Sham Procedure | Arm Label: B: Faricimab 6 mg PTI; Type: EXPERIMENTAL; Interventions: Drug: Faricimab, Procedure: Sham Procedure | Arm Label: C: Aflibercept 2 mg Q8W; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aflibercept, Procedure: Sham Procedure | Intervention Type: DRUG; Name: Aflibercept; Assigned to Arm(s): C: Aflibercept 2 mg Q8W | Intervention Type: DRUG; Name: Faricimab; Assigned to Arm(s): A: Faricimab 6 mg Q8W, B: Faricimab 6 mg PTI | Intervention Type: PROCEDURE; Name: Sham Procedure; Assigned to Arm(s): A: Faricimab 6 mg Q8W, B: Faricimab 6 mg PTI, C: Aflibercept 2 mg Q8W
B: Arm Label: Saline Injection; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Arm Label: Ranibizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Saline Injection
C: Arm Label: ESBA1008; Type: EXPERIMENTAL; Interventions: Drug: ESBA1008 solution | Arm Label: EYLEA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aflibercept | Intervention Type: DRUG; Name: ESBA1008 solution; Assigned to Arm(s): ESBA1008 | Intervention Type: DRUG; Name: Aflibercept; Assigned to Arm(s): EYLEA
D: Arm Label: Arm A: 0.3 mg Ranibizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab | Arm Label: Arm B: 1.5 mg Faricimab; Type: EXPERIMENTAL; Interventions: Drug: Faricimab | Arm Label: Arm C: 6 mg Faricimab; Type: EXPERIMENTAL; Interventions: Drug: Faricimab | Intervention Type: DRUG; Name: Faricimab; Assigned to Arm(s): Arm B: 1.5 mg Faricimab, Arm C: 6 mg Faricimab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Arm A: 0.3 mg Ranibizumab

Answer: C